We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02014428
First Posted: December 18, 2013
Last Update Posted: December 18, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AGUNCO Obstetrics and Gynecology Centre
  Purpose
To evaluate the effectiveness of low molecular weight hyaluronic acid oral tablets for the treatment of atrophic vaginitis.

Condition Intervention Phase
Atrophic Vaginitis Dietary Supplement: Hyaluronic acid Drug: Placebo Phase 4

Study Type: Interventional

Resource links provided by NLM:


Further study details as provided by AGUNCO Obstetrics and Gynecology Centre:

Primary Outcome Measures:
  • Atrophic vaginal changes [ Time Frame: Change from baseline epithelium at 3 months ]
    Morphometric analysis of biopsies.


Secondary Outcome Measures:
  • Assessment of Itching [ Time Frame: Change from baseline Itching at 3 months ]
    Scale: absent, mild, moderate, severe.

  • Assessment of Burning [ Time Frame: Change from baseline Burning at 3 months ]
    Scale: absent, mild, moderate, severe.

  • Assessment of Dyspareunia [ Time Frame: Change from baseline Dyspareunia at 3 months ]
    Scale: absent, mild, moderate, severe.


Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Hyaluronic acid
220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
Dietary Supplement: Hyaluronic acid
Placebo Comparator: Placebo
two tablets/day for 10 days, and subsequently one tablet/day for three months
Drug: Placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • at least 12 months postmenopausal
  • mucosal atrophy and the main bothersome related symptoms, such as itching, burning, and dyspareunia.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02014428


Locations
Italy
Department of Gynecological, Obstetric Sciences and Reproductive Medicine, University of Messina.
Messina, Italy
Sponsors and Collaborators
AGUNCO Obstetrics and Gynecology Centre
  More Information

Responsible Party: AGUNCO Obstetrics and Gynecology Centre
ClinicalTrials.gov Identifier: NCT02014428     History of Changes
Other Study ID Numbers: HA-123
First Submitted: December 9, 2013
First Posted: December 18, 2013
Last Update Posted: December 18, 2013
Last Verified: December 2013

Additional relevant MeSH terms:
Vaginitis
Atrophic Vaginitis
Atrophy
Pathological Conditions, Anatomical
Vaginal Diseases
Genital Diseases, Female
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents